OLUCHI CHILAKA: Open Payments
NPI 1336651520 · DENVILLE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,412 in 284 payments from 16 companies in 2025. Trend: 2023 $4,260 · 2024 $6,102 · 2025 $6,412
Food & beverage: $6,183Education: $230
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 55 | $1,346 |
| Neurocrine BioSciences, Inc. | 41 | $809 |
| Alkermes, Inc. | 31 | $713 |
| Otsuka America Pharmaceutical, Inc. | 34 | $677 |
| Vanda Pharmaceuticals Inc. | 25 | $626 |
| E.R. Squibb & Sons, L.L.C. | 23 | $562 |
| ABBVIE INC. | 15 | $547 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $345 |
| Supernus Pharmaceuticals, Inc. | 21 | $297 |
| Lundbeck LLC | 9 | $155 |
Products named: UZEDY, INGREZZA, REXULTI, FANAPT, VRAYLAR, COBENFY, ARISTADA, CAPLYTA.
Industry payments across NJ — which companies pay providers there.
